Blog
Product strategy, conversion systems, and telehealth operations for teams building modern care journeys.
After the Votes: Turning July's FDA Peptide Meeting Into a 2027 Roadmap
The FDA's advisory committee spent two days last week reviewing seven of the most-requested peptides in consumer health. Whatever your read on the individual votes, the strategic picture is now clearer than it has been in years: the review pathway is real, the timeline runs through rulemaking, and the operators who use the interval to build governance, demand, and infrastructure will own the category when the rules settle. Here is the after-meeting roadmap.
The Membership-Model Longevity Clinic: Labs, Peptides, Hormones, One Platform
A wave of longevity clinics launched this summer with the same architecture: an annual membership wrapping comprehensive labs, clinician review, and a protocol layer spanning hormones, peptides where compliant, and metabolic medications. The model works because it matches how longevity patients actually think, in systems and years rather than prescriptions and months. Here is the full blueprint, from diagnostic spine to renewal economics.
The Longevity Stack: Combining NAD+, Peptides, GLP-1, and Rapamycin in One DTC Program
Longevity patients rarely want a single compound. They want a stack. Combining NAD+, peptides, GLP-1, and rapamycin in one DTC program is a real opportunity, but only if intake, provider scope, sequencing, billing, and compliance are built for a multi-compound model instead of bolted together from separate funnels.
NAD+ Delivery Formats Compared: IV vs. Injection vs. Nasal Spray vs. Oral Precursors
NAD+ is the same molecule no matter how a patient takes it, but the delivery format changes everything about evidence, cost, adherence, compliance, and patient experience. This is how DTC telehealth teams should compare IV, subcutaneous injection, nasal spray, and oral precursors before building a NAD+ program.